Cargando…

小剂量利妥昔单抗治疗12例难治/复发原发性自身免疫性溶血性贫血患者疗效分析

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342200/
https://www.ncbi.nlm.nih.gov/pubmed/29365406
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.12.016
_version_ 1783555402115317760
collection PubMed
description
format Online
Article
Text
id pubmed-7342200
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73422002020-07-16 小剂量利妥昔单抗治疗12例难治/复发原发性自身免疫性溶血性贫血患者疗效分析 Zhonghua Xue Ye Xue Za Zhi 短篇论著 Editorial office of Chinese Journal of Hematology 2017-12 /pmc/articles/PMC7342200/ /pubmed/29365406 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.12.016 Text en 2017年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 短篇论著
小剂量利妥昔单抗治疗12例难治/复发原发性自身免疫性溶血性贫血患者疗效分析
title 小剂量利妥昔单抗治疗12例难治/复发原发性自身免疫性溶血性贫血患者疗效分析
title_full 小剂量利妥昔单抗治疗12例难治/复发原发性自身免疫性溶血性贫血患者疗效分析
title_fullStr 小剂量利妥昔单抗治疗12例难治/复发原发性自身免疫性溶血性贫血患者疗效分析
title_full_unstemmed 小剂量利妥昔单抗治疗12例难治/复发原发性自身免疫性溶血性贫血患者疗效分析
title_short 小剂量利妥昔单抗治疗12例难治/复发原发性自身免疫性溶血性贫血患者疗效分析
title_sort 小剂量利妥昔单抗治疗12例难治/复发原发性自身免疫性溶血性贫血患者疗效分析
topic 短篇论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342200/
https://www.ncbi.nlm.nih.gov/pubmed/29365406
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2017.12.016
work_keys_str_mv AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī
AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī
AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī
AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī
AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī
AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī
AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī
AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī
AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī
AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī
AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī
AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī
AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī
AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī
AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī
AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī
AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī
AT xiǎojìliànglìtuǒxīdānkàngzhìliáo12lìnánzhìfùfāyuánfāxìngzìshēnmiǎnyìxìngróngxuèxìngpínxuèhuànzhěliáoxiàofēnxī